Strategies for Tailored Antiplatelet Therapy after Percutaneous Coronary Intervention: Unraveling Complexities, Embracing Nuances

• References

• 1 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49 (14) 1505-1516
• 2 Capodanno D, Angiolillo DJ. Personalised antiplatelet therapies for coronary artery disease: what the future holds. Eur Heart J 2023; 44 (32) 3059-3072
• 3 Birocchi S, Rocchetti M, Minardi A, Podda GM, Squizzato A, Cattaneo M. Guided anti-P2Y12 therapy in patients undergoing PCI: 3 systematic reviews with meta-analyses of randomized controlled trials with homogeneous design. Thromb Haemost 2024; 124 (05) 482-496
• 4 Lyu SQ, Yang YM, Zhu J. et al. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Platelets 2020; 31 (08) 971-980
• 5 Tang B, Wang X, Wang X, Liu L, Ma Z. Genotype-guided antiplatelet therapy versus standard therapy for patients with coronary artery disease: an updated systematic review and meta-analysis. J Pharm Pharm Sci 2022; 25: 9-23
• 6 Greco A, Capodanno D, Angiolillo DJ. The conundrum surrounding racial differences on ischaemic and bleeding risk with dual anti-platelet therapy. Thromb Haemost 2019; 119 (01) 9-13
• 7 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
• 8 Capodanno D, Mehran R, Krucoff MW. et al. defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium. Circulation 2023; 147 (25) 1933-1944
• 9 Neumann FJ, Sousa-Uva M, Ahlsson A. et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40 (02) 87-165
• 10 Lawton JS, Tamis-Holland JE, Bangalore S. et al; Writing Committee Members. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79 (02) e21-e129
• 11 Angiolillo DJ, Capodanno D, Danchin N. et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE SCORE. JACC Cardiovasc Interv 2020; 13 (05) 606-617
• 12 Zhang Y, Zhang Y, Shi X. et al. Clopidogrel versus ticagrelor in CYP2C19 loss-of-function allele noncarriers: a real-world study in China. Thromb Haemost 2022; 122 (05) 842-852
• 13 Gorog DA, Jeyalan V, Markides RIL, Navarese EP, Jeong YH, Farag M. Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (08) 773-792
• 14 Pereira NL, Farkouh ME, So D. et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA 2020; 324 (08) 761-771
• 15 Kuno T, Fujisaki T, Shoji S. et al. Comparison of unguided de-escalation versus guided selection of dual antiplatelet therapy after acute coronary syndrome: a systematic review and network meta-analysis. Circ Cardiovasc Interv 2022; 15 (08) e011990